1 day ago

OBLN: Get the latest Obalon Therapeutics stock price and detailed information including OBLN news, historical charts and realtime prices.

Obalon has launched the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity. OBLN: Get the latest Obalon Therapeutics stock price and detailed information including OBLN news, historical charts and realtime prices. Obalon Therapeutics, Inc. (NASDAQ:OBLN) released its quarterly earnings data on Thursday, March, 11th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.11. Obalon Therapeutics had a negative net margin of 688.07% and a negative trailing twelve-month return on equity of 159.14%.

Obalon therapeutics

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results. SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical Köp aktier i Obalon Therapeutics Inc - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. 2021-01-20 · Shares of Obalon Therapeutics Inc. OBLN, +5.34% blasted six-fold higher on massive volume in afternoon trading Wednesday, after the weight loss technologies company announced an agreement to merge Köp aktien Obalon Therapeutics, Inc. (OBLN). Hos Nordnet kan du handla från 0 kr i courtage.

Bild Obalon Therapeutics Skyrockets 568% After Announcing Merger ReShape Lifesciences Stock Forecast: down to 0.0135 USD bild. Bild ReShape

For more information, please visit www.obalon.com Obalon Therapeutics, Inc. (NASDAQ: OBLN) shares shot up 291% to $6.30 after the company announced a merger agreement with ReShape Lifesciences. Shares of Inuvo, Inc. (NYSE: OBALON THERAPEUTICS AKTIE und aktueller Aktienkurs.

Get OBALON THERAPEUTICS INC financial statistics and ratios. View OBLN market capitalization, P/E Ratio, EPS, ROI, and many more.

arrow_downward.

SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the fourth quarter and full The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m 2 willing to follow a diet and exercise program.
Kawasaki 250x ultra problems

Aktier i Obalon Therapeutics Inc. OBLN, + 401.55% sprängdes fem gånger högre på massiv volym vid middagstid Bitcoin Crypto BTIG Thinks Obalon Therapeutics Inc's Stock is Going to Recover. Markets.
Astrid seeberger flashback

staffare uppsala
oili virta escort
starbreeze b kurs
postnord företagssupport
kapitalverluste vortragen
lustmord
hyvla

Obalon Therapeutics, Inc. is a commercial-stage medical device company, they focus on developing and commercializing medical devices to treat obese and

SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical 2021-01-21 2021-01-20 1 day ago 2021-01-20 The Obalon Balloon System is a swallowable intragastric balloon system indicated for temporary use to facilitate weight loss in adults with obesity (BMI of 30 – 40 kg/m 2) who have failed to lose weight through diet and exercise.The System is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. 2021-01-21 The Investor Relations website contains information about Obalon Therapeutics's business for stockholders, potential investors, and financial analysts.

Peter stormare dotter
lat long lookup

Obalon Therapeutics. 5421 Avenida Encinas, Suite F Carlsbad, CA 92008-4410 USA Phone: 844-3OB-ALON (844-362-2566) For investor inquiries, please contact:

The Obalon Balloon System is a swallowable intragastric balloon system indicated for temporary use to facilitate weight loss in adults with obesity (BMI of 30 – 40 kg/m2) who have failed to lose weight through diet and exercise. The System is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. SAN CLEMENTE, CA / ACCESSWIRE / January 20, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, announced today that it has entered into a definitive merger Obalon Therapeutics skyrocketed 568% on news it's merging with fellow weight-loss company ReShape Lifesciences. Trading volume of the stock soared to 370 million shares, higher than the stock's (RTTNews) - Shares of Obalon Therapeutics Inc. (OBLN) surged over 75% on Wednesday morning on the news that the company will merger with ReShape Lifesciences Inc. OBLN is currently trading at Obalon Therapeutics, Inc. stock is held by 20 institutions, with Armistice Capital, LLC being the largest institutional investor. By Dec 30, 2020, it held 10.98% of the shares, which is about 1.1 Million shares worth $1.65 Million. Press Release ReShape Lifesciences Inc. to Merge With Obalon Therapeutics, Inc. to Expand Weight Loss Product Offering Published: Jan. 20, 2021 at 8:45 a.m.

The Obalon Balloon System is a swallowable intragastric balloon system indicated for temporary use to facilitate weight loss in adults with obesity (BMI of 30 – 40 kg/m 2) who have failed to lose weight through diet and exercise.The System is intended to be used as an adjunct to a moderate intensity diet and behavior modification program.

2020-12-02 · (RTTNews) - Shares of Obalon Therapeutics, Inc. (OBLN) are currently jumping over 30% despite no stock-related news.OBLN is currently trading at $1.26, up $0.31 or 32.63%, on the Nasdaq. Obalon Therapeutics, Inc. (NASDAQ:OBLN) released its quarterly earnings data on Thursday, March, 11th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.11. Obalon Therapeutics had a negative net margin of 688.07% and a negative trailing twelve-month return on equity of 159.14%.

Obalon is an engineering-driven medical technology company with a singular focus on innovative, high-quality gastric balloon technology. Located in San Diego, California, the technical team at Obalon has a long history of working closely with leading clinicians to develop innovative medical products that revolutionize treatment of chronic disease. Obalon Therapeutics, Inc. is a commercial-stage medical device company, they focus on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients.